In 67 immunocompromised Sjögren's disease patients v 201 non-immunosuppressed controls, seroconversion after recombinant zoster vaccine was lower (90.6% v 99.5%; P<0.001) with lower titres; cellular responses were similar and no serious vaccine-related AEs occurred.
RCTn = 268
Pasoto et al. Lower magnitude of humoral response to recombinant herpes zoster vaccine in immunocompromised Sjögren's disease patients: evidence from a randomized double-blinded placebo-controlled trial